Cited by 30Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report

Open access
Chan, Herng Nieng, Rush, A. John, Nierenberg, Andrew A., Trivedi, Madhukar, Wisniewski, Stephen R., Balasubramani, G. K., Friedman, Edward S., Gaynes, Bradley N. +3 more·2012·The International Journal of Neuropsychopharmacology

Abstract

The objective of this paper was to determine whether the presence of more vs. fewer anxious symptom features, at baseline, are associated with other clinical features and treatment outcomes in out-patients with major depressive disorder (MDD). This single-blind, randomized trial enrolled 665 MDD out-patients to compare the efficacy of two antidepressant medication combinations against escitalopram after 12-wk acute treatment and follow-up (total 28 wk). The sample was divided into those with greater (vs. fewer) anxiety features using the anxiety/somatization subscale of the baseline 17-item Hamilton Rating Scale for Depression. Baseline sociodemographic and clinical features, treatment features and outcomes compared these two groups. Overall, 74.7% of participants met the threshold for 'anxious features'. They were more likely to be female, have other concurrent anxiety disorders, more severe depression, more lethargic and melancholic features and poorer cognitive and physical functioning, quality of life and work and social adjustment. In acute treatment, participants with anxious features received comparatively higher doses of mirtazapine and venlafaxine and reported more side-effects. The groups with and without anxious features did not differ in treatment outcomes and side-effect burden. Despite being associated with a distinct clinical profile, baseline anxious features were not clinically useful in predicting acute treatment outcomes or differential treatment response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145711001660

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chan, H. N., Rush, A. J., Nierenberg, A. A., Trivedi, M., Wisniewski, S. R., Balasubramani, G. K., Friedman, E. S., Gaynes, B. N., Davis, L., Morris, D., & Fava, M.
Affiliations
  • Singapore General Hospital (SG)
  • National University of Singapore (SG)
  • Massachusetts General Hospital (US)
  • The University of Texas Southwestern Medical Center (US)
  • University of Pittsburgh (US)
  • University of North Carolina at Chapel Hill (US)
  • University of Alabama (US)
  • New York State Psychiatric Institute (US)
Corresponding author
Trivedi, Madhukar
Venue
The International Journal of Neuropsychopharmacology
Published
2011-12-01
Volume
15
Issue
10
Pages
1387-1399
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2149127858
Cited by
30
References
49
Citations by year
2026: 3 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 1
FWCI
0.70
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion)
Funders
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • University of Texas Southwestern Medical Center
  • National Institutes of Health (n01mh90003-26-0-0)
  • National Institute of Mental Health (N01‐MH‐90003)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
Keywords
major depressive disorder, anxiety comorbidity, antidepressant combination therapy, escitalopram, mirtazapine, venlafaxine, treatment response prediction, antidepressant side effects, somatization, endogenous depression, quality of life, work and social adjustment
MeSH terms
Adolescent, Adult, Aged, Ambulatory Care, Antidepressive Agents, Anxiety, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Male, Single-Blind Method, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review